This site uses features not supported by Internet Explorer.

MUST-SEE First Time Ever Webinar (Zostavax)
< Back to Webinars
MUST-SEE First Time Ever Webinar (Zostavax)

Zostavax is a vaccine for shingles manufactured by the pharmaceutical company Merck, and approved by the U.S. Food and Drug Administration in 2006. It was designed to reduce the risk of getting herpes zoster – a painful and debilitating condition commonly known as “shingles” - in individuals ages 50 years and older.

It was the only approved shingles vaccine in the United States until late 2017, and has been administered more than 36 million times in the last 10 years. It has earned billions of dollars for Merck in the last decade, with $749 million coming in just 2016.

What You Can Expect to Learn

  • What is Shingles?
  • What is Zostavax?
  • Who is allegedly harmed by Zostavax?
  • How are they allegedly harmed?
  • Why are individuals allegedly harmed by Zostavax filing lawsuits?
  • What is the current state of Zostavax litigation?
  • What role is Morgan & Morgan playing in Zostavax litigation?


We're sorry you missed the webinar. You can still see a recording by filling out the form below.

Gain Access

Presented By

  • Mike Morgan - Morgan & Morgan
  • Michael Goetz - Morgan & Morgan
  • Nicole Georges - Morgan & Morgan